Exploration of the mechanism of Traditional Chinese Medicine for anxiety and depression in patients with diarrheal irritable bowel syndrome based on network pharmacology and meta-analysis
Erforschung des Mechanismus der Traditionellen Chinesischen Medizin bei Angst und Depression bei Patient:innen mit diarrhöischem Reizdarmsyndrom anhand von Netzwerkpharmakologie und Metaanalyse
Frontiers in Pharmacology · 21.05.2024 · 15
DOI: 10.3389/fphar.2024.1404738 ↗Auf einen Blick
25 RCTs mit 2055 Patient:innen zeigen: Chinese Herbal Medicine war mit besseren IBS-D-, Depressions- und Angstwerten sowie weniger Rückfällen verbunden.
Fragestellung
Wie wirksam ist Chinese Herbal Medicine bei IBS-D mit Angst und Depression, und welche möglichen Mechanismen werden beschrieben?
Methode
Systematische Übersichtsarbeit mit Metaanalyse und Netzwerkpharmakologie; 25 randomisierte kontrollierte Studien.
Ergebnisse
IBS-D: OR 4,01 (95 %-KI 2,99–5,36; I2 = 0%). Depression: SMD -1,08 (95 %-KI -1,30 bis -0,86). Angst: HAMA SMD -1,29 (95 %-KI -1,68 bis -0,91); SAS SMD -1,75 (95 %-KI -2,55 bis -0,95). Rückfall: OR 0,30 (95 %-KI 0,20–0,44).
Schlussfolgerung der Autor:innen
Chinese Herbal Medicine bietet nach Autor:innen einen vielversprechenden und sicheren Behandlungsansatz für IBS-D mit Angst und Depression und könnte praktisch einsetzbar sein.
Kernaussagen
- 25 RCTs mit 2055 Patient:innen
- Verbesserungen bei IBS-D, Depression und Angst
- Niedrigere Rückfallrate unter CHM
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 21.05.2024. Verfasst von Chen Bai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Depression
Abstract (Originalsprache)
Background
The efficacy of Chinese herbal medicine (CHM) in managing irritable bowel syndrome with diarrhea (IBS-D) accompanied by anxiety and depression remains uncertain. Thus, a systematic review was carried out employing meta-analysis and network pharmacology to ascertain the efficacy and underlying mechanisms of CHM therapy.
Methods
By conducting a systematic review, including literature search, screening, and data extraction, we identified 25 randomized controlled trials to assess CHM’s effectiveness in treating irritable bowel syndrome alongside anxiety and depression. Network pharmacology was utilized to scrutinize the metabolite utility of CHM in addressing this condition. Potential primary mechanisms were synthesized using information sourced from the PubMed database.
Results
Twenty-five studies, including 2055 patients, were analyzed, revealing significant treatment efficacy for IBS-D in the trial group compared to controls [OR = 4.01, 95% CI (2.99, 5.36), I 2 = 0%] Additionally, treatment for depression [SMD = −1.08, 95% CI (-1.30, −0.86), p < 0.00001, I 2 = 68%; SDS: SMD = -1.69, 95% CI (-2.48, −0.90), p < 0.0001, I 2 = 96%] and anxiety [HAMA: SMD = -1.29, 95% CI (-1.68, −0.91), p < 0.00001, I 2 = 89%; SAS: SMD = -1.75, 95% CI (-2.55, −0.95), p < 0.00001, I 2 = 96%] significantly improved in the trial group. Furthermore, the trial group exhibited a significantly lower disease relapse rate [OR = 0.30, 95% CI (0.20, 0.44), p < 0.00001, I 2 = 0%]. CHM treatment consistently improved IBS severity (IBS-SSS) and symptom scores. Network pharmacology analysis identified key chemical metabolites in traditional Chinese medicine formulations, including Beta-sitosterol, Stigmasterol, Quercetin, Naringenin, Luteolin, Kaempferol, Nobiletin, Wogonin, Formononetin, and Isorhamnetin. Utilizing the STRING database and Cytoscape v3.9.0 software, a protein-protein interaction (PPI) network revealed the top eight key targets: IL-6, TNF, PPARG, PTGS2, ESR1, NOS3, MAPK8, and AKT1, implicated in anti-inflammatory responses, antioxidant stress modulation, and neurotransmitter homeostasis maintenance.
Conclusion
Chinese Herbal Medicine (CHM) offers a promising and safe treatment approach for patients dealing with Diarrheal Irritable Bowel Syndrome (IBS-D) accompanied by anxiety and depression; thus, indicating its potential for practical implementation. The most active metabolites of CHM could simultaneously act on the pathological targets of IBS-D, anxiety, and depression.The diverse scope of CHM’s therapeutic role includes various aspects and objectives, underscoring its potential for broad utilization.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
- Department of Medical Equipment, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Psychosomatic Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Zitieren
APA
Bai, C., Wang, J., Wang, Y., Liu, H., Li, J., Wang, S., Bai, Z., & Guo, R. (2024). Exploration of the mechanism of Traditional Chinese Medicine for anxiety and depression in patients with diarrheal irritable bowel syndrome based on network pharmacology and meta-analysis. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1404738
Vancouver
Bai C, Wang J, Wang Y, Liu H, Li J, Wang S, et al. Exploration of the mechanism of Traditional Chinese Medicine for anxiety and depression in patients with diarrheal irritable bowel syndrome based on network pharmacology and meta-analysis. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1404738
BibTeX
@article{Bai2024,
author = {Bai, Chen and Wang, Junyi and Wang, Yifan and Liu, Haoqi and Li, Jiaxiu and Wang, Siyi and Bai, Zhen and Guo, Rongjuan},
title = {Exploration of the mechanism of Traditional Chinese Medicine for anxiety and depression in patients with diarrheal irritable bowel syndrome based on network pharmacology and meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1404738}
}
EUVIMED